Investigating the role of the HDAC3 pathway in lung cancer with LKB1 mutations
Official title: The HDAC3 pathway in LKB1-mutant lung cancer and senescence
Funded at Northwestern University at Chicago · NIH-10978199 · Data updated 2026-11-12
This study is looking at how changes in the LKB1 gene affect lung cancer, especially the non-small cell type, and it hopes to find new ways to treat patients by understanding how certain proteins help tumors grow.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $191,052 |
| NIH project number | 5K22CA251636-03 |
| Project ID | NIH-10978199 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who have mutations in the LKB1 gene.
✕Less likely to help
Patients with lung cancer who do not have LKB1 mutations may not benefit from the findings of this research.
What this research studies
This research focuses on understanding how mutations in the LKB1 gene contribute to lung cancer, particularly non-small cell lung cancer (NSCLC). It explores the role of the HDAC3 protein complex in promoting tumor growth and its interaction with other factors that influence cancer cell behavior. By examining the unique biological characteristics of LKB1-mutant tumors, the study aims to identify potential therapeutic targets and improve treatment options for affected patients.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with LKB1-mutant lung cancer.
How similar studies have gone: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this area.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Eichner, Lillian J. — Northwestern University at Chicago
- Study coordinator: Eichner, Lillian J.
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.